Lip and Oral Cavity Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LPN002 MIFTS: 60	Lip and Oral Cavity Cancer Categories: Cancer diseases, Oral diseases, Rare diseases, Smell/Taste diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Lip and Oral Cavity Cancer

MalaCards integrated aliases for Lip and Oral Cavity Cancer:

Name: Lip and Oral Cavity Cancer ¹⁹

Oral Cancer ¹⁹ ⁵³ ⁴¹ ² ⁷⁵

Lip and Oral Cavity Carcinoma ⁵ ⁷¹

Malignant Neoplasm of Mouth ⁷¹

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Smell/Taste diseases Oral diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms of lip, oral cavity and pharynx

Malignant neoplasm of other and unspecified parts of mouth

Malignant neoplasm: Mouth, unspecified

External Ids:

ICD10 ³¹ C06.9

UMLS ⁷¹ C0153381 C0220641

Sources

Summaries for Lip and Oral Cavity Cancer

CDC: ² In 2012, there were nearly 40,000 new cases of cancer of the oral cavity and pharynx diagnosed in the United States and nearly 9,000 deaths. The 5-year survival rate for these cancers is about 59 percent. Mortality from oral cancer is nearly twice as high in some minorities (especially black males) as it is in whites. Preventing high risk behaviors, that include cigarette, cigar or pipe smoking, use of smokeless tobacco, and excessive use of alcohol are critical in preventing oral cancers. Early detection is key to increasing the survival rate for these cancers. Oral Human Papilloma Virus (HPV), the most common sexually transmitted disease, can cause cancers in the back of the throat, called "oropharyngeal cancers." More research is needed to determine whether HPV itself causes oropharyngeal cancers, or if other factors (such as smoking or chewing tobacco) interact with HPV to cause these cancers.

MalaCards based summary: Lip and Oral Cavity Cancer, also known as oral cancer, is related to leukoplakia and oral submucous fibrosis, and has symptoms including snoring and halitosis. An important gene associated with Lip and Oral Cavity Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Disease and Signal Transduction. The drugs Dopamine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include tongue, lymph node and endothelial, and related phenotypes are Decreased viability and Decreased substrate adherent cell growth

MedlinePlus: ⁴¹ Oral cancer can form in any part of the mouth. Most oral cancers begin in the flat cells that cover the surfaces of your mouth, tongue, and lips. Anyone can get oral cancer, but the risk is higher if you are male, use tobacco, drink lots of alcohol, have HPV, or have a history of head or neck cancer. Frequent sun exposure is also a risk factor for lip cancer. Symptoms of oral cancer include : White or red patches in your mouth A mouth sore that won't heal Bleeding in your mouth Loose teeth Problems or pain with swallowing A lump in your neck An earache Tests to diagnose oral cancer include a physical exam, endoscopy, biopsy, and imaging tests. Oral cancer treatments may include surgery, radiation therapy, and chemotherapy. Some patients have a combination of treatments. NIH: National Cancer Institute

GARD: ¹⁹ A carcinoma arising in the lip or oral cavity. Most oral cavity carcinomas are squamous cell carcinomas of the tongue, buccal mucosa, or gums. Less frequent morphologic variants include mucoepidermoid carcinoma and adenocarcinoma. Lip carcinomas are usually basal cell or squamous cell carcinomas.

Wikipedia: ⁷⁵ Oral cancer, also known as mouth cancer, is cancer of the lining of the lips, mouth, or upper throat. In... more...

Sources

Related Diseases for Lip and Oral Cavity Cancer

Diseases related to Lip and Oral Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 731)

#	Related Disease	Score	Top Affiliating Genes
1	leukoplakia	31.6	KRT13 GSTM1 CYP1A1
2	oral submucous fibrosis	31.2	TP53 MIR21 EGFR CYP1A1
3	lichen planus	31.2	TP53 MIR31 KRT13
4	head and neck cancer	31.2	TP53 PIK3CA MIR31 MIR21 HRAS EGFR
5	lip cancer	31.0	TP53 MIR345 CDKN2A
6	papilloma	31.0	TP53 RB1 KRT13 EGFR CDKN2A CCND1
7	tongue carcinoma	31.0	TP53 RB1 MIR31 MIR21 EGFR CDKN2A
8	verrucous carcinoma	30.9	TP53 PIK3CA EGFR CDKN2A
9	oropharynx cancer	30.8	TP53 PIK3CA MIR21 KIT HRAS EGFR
10	squamous cell carcinoma	30.6	TP53 STK11 RB1 PIK3CA KRT13 HRAS
11	exanthem	30.6	KIT HRAS EGFR
12	ataxia-telangiectasia	30.5	TP53 STK11 BRAF ABL1
13	keratoacanthoma	30.5	TP53 PIK3CA EGFR
14	salivary gland carcinoma	30.4	TP53 KIT EGFR CDKN2A
15	retinoblastoma	30.4	TP53 RB1 CDKN2A CCND1 ABL1
16	sarcoma	30.3	TP53 RB1 PIK3CA KIT HRAS BRAF
17	laryngeal benign neoplasm	30.3	TP53 PIK3CA EGFR CDKN2A CCND1
18	suppressor of tumorigenicity 3	30.3	TP53 RB1 CDKN2A
19	familial adenomatous polyposis	30.3	TP53 HRAS CCND1 BRAF
20	squamous cell carcinoma, head and neck	30.3	TP53 RB1 RARB PIK3CA MIR31 MIR21
21	basaloid squamous cell carcinoma	30.3	TP53 KIT CDKN2A
22	anogenital venereal wart	30.3	TP53 RB1 CDKN2A
23	keratosis	30.3	TP53 PIK3CA HRAS EGFR CDKN2A
24	basal cell carcinoma	30.2	TP53 GSTM1 EGFR CYP1A1 CDKN2A
25	larynx cancer	30.2	TP53 MIR31 MIR21 GSTM1 EGFR CCND1
26	b-lymphoblastic leukemia/lymphoma	30.1	KIT CDKN2A ABL1
27	leukemia	30.1	TP53 KIT CDKN2A CCND1 BRAF ABL1
28	myoma	30.0	TP53 KIT EGFR
29	nasopharyngeal carcinoma	30.0	TP53 PIK3CA MIR31 MIR21 GSTM1 EGFR
30	adenoid cystic carcinoma	30.0	TP53 PIK3CA LRRC56 KIT HRAS EGFR
31	lipomatosis, multiple	30.0	TP53 PIK3CA KIT
32	skin carcinoma	30.0	TP53 MIR31 MIR21 KIT HRAS EGFR
33	inherited cancer-predisposing syndrome	29.9	TP53 STK11 RB1 KIT EGFR CDKN2A
34	bap1 tumor predisposition syndrome	29.9	TP53 STK11 RB1 KIT EGFR CDKN2A
35	leukemia, chronic myeloid	29.9	TP53 KIT HRAS EGFR CCND1 BRAF
36	hypopharynx cancer	29.9	TP53 EGFR CDKN2A CCND1
37	skin melanoma	29.9	TP53 PIK3CA MIR21 LRRC56 KIT HRAS
38	female breast cancer	29.9	TP53 EGFR CDKN2A CCND1
39	human papillomavirus infectious disease	29.8	TP53 PIK3CA MIR31 MIR21 KRT13 HRAS
40	adenocarcinoma	29.8	TP53 STK11 RB1 PIK3CA HRAS EGFR
41	li-fraumeni syndrome	29.8	TP53 STK11 RB1 PIK3CA HRAS EGFR
42	kidney cancer	29.7	TP53 PIK3CA MIR21 EGFR CDKN2A
43	anus cancer	29.7	TP53 RB1 PIK3CA HRAS EGFR CDKN2A
44	laryngeal squamous cell carcinoma	29.7	TP53 MIR21 GSTM1 EGFR CYP1A1 CDKN2A
45	cervical squamous cell carcinoma	29.7	TP53 PIK3CA EGFR CDKN2A CCND1
46	adenoma	29.7	TP53 PIK3CA HRAS CDKN2A CCND1 BRAF
47	acute promyelocytic leukemia	29.7	TP53 RARB PIK3CA KIT HRAS CCND1
48	hematologic cancer	29.7	RB1 MIR31 MIR21 KIT HRAS ABL1
49	wilms tumor 1	29.7	TP53 KIT HRAS EGFR CDKN2A CCND1
50	tonsil cancer	29.6	TP53 PIK3CA KIT EGFR CDKN2A CCND1

Graphical network of the top 20 diseases related to Lip and Oral Cavity Cancer:

Sources

Symptoms & Phenotypes for Lip and Oral Cavity Cancer

UMLS symptoms related to Lip and Oral Cavity Cancer:

snoring; halitosis

GenomeRNAi Phenotypes related to Lip and Oral Cavity Cancer according to GeneCards Suite gene sharing:

²⁵ (show all 41)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.69	BRAF EGFR HRAS PIK3CA
2	Decreased viability	GR00055-A-2	10.69	BRAF EGFR HRAS PIK3CA
3	Decreased viability	GR00221-A-1	10.69	EGFR HRAS PIK3CA ABL1 CDKN2A KIT
4	Decreased viability	GR00221-A-2	10.69	HRAS PIK3CA ABL1
5	Decreased viability	GR00221-A-3	10.69	HRAS ABL1 CDKN2A
6	Decreased viability	GR00221-A-4	10.69	BRAF EGFR PIK3CA CDKN2A
7	Decreased viability	GR00249-S	10.69	BRAF
8	Decreased viability	GR00301-A	10.69	BRAF KIT
9	Decreased viability	GR00342-S-1	10.69	ABL1
10	Decreased viability	GR00342-S-2	10.69	ABL1
11	Decreased viability	GR00342-S-3	10.69	ABL1
12	Decreased viability	GR00381-A-1	10.69	BRAF
13	Decreased viability	GR00402-S-2	10.69	PIK3CA
14	Decreased substrate adherent cell growth	GR00193-A-1	9.8	KIT
15	Decreased substrate adherent cell growth	GR00193-A-2	9.8	ABL1 KIT
16	Decreased substrate adherent cell growth	GR00193-A-3	9.8	BRAF
17	Decreased substrate adherent cell growth	GR00193-A-4	9.8	ABL1 BRAF KIT
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-10	9.77	RARB
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	9.77	ABL1
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-152	9.77	KIT
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	9.77	ABL1 KIT
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-165	9.77	KRT13
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-170	9.77	KIT
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-184	9.77	RARB
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-189	9.77	KRT13
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	9.77	KRT13
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-211	9.77	KRT13
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	9.77	ABL1 RARB
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-23	9.77	RARB
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-30	9.77	ABL1 KIT
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-33	9.77	KRT13
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-34	9.77	ABL1 KRT13 RARB
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	9.77	ABL1
34	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	9.77	ABL1
35	Increased shRNA abundance (Z-score > 2)	GR00366-A-61	9.77	KIT
36	Increased shRNA abundance (Z-score > 2)	GR00366-A-81	9.77	KRT13
37	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.77	ABL1 KIT
38	Increased shRNA abundance (Z-score > 2)	GR00366-A-9	9.77	KIT
39	Increased shRNA abundance (Z-score > 2)	GR00366-A-99	9.77	KIT
40	Increased cell viability after pRB stimulation	GR00230-A-1	9.46	ABL1 EGFR KIT STK11
41	Decreased viability in pancreas lineage	GR00235-A	9.13	CCND1 RARB TP53

MGI Mouse Phenotypes related to Lip and Oral Cavity Cancer:

⁴⁵ (show all 24)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	10.44	ABL1 BRAF CCND1 CDK2AP1 CDKN2A CYP1A1
2	nervous system	MP:0003631	10.4	ABL1 BRAF CCND1 CDKN2A EGFR GSTM1
3	homeostasis/metabolism	MP:0005376	10.4	ABL1 BRAF CCND1 CDKN2A CYP1A1 EGFR
4	endocrine/exocrine gland	MP:0005379	10.37	ABL1 BRAF CCND1 CDKN2A CYP1A1 EGFR
5	neoplasm	MP:0002006	10.35	BRAF CCND1 CDKN2A EGFR HRAS KIT
6	normal	MP:0002873	10.35	ABL1 BRAF CCND1 CYP1A1 EGFR HRAS
7	muscle	MP:0005369	10.32	ABL1 BRAF CDKN2A EGFR HRAS KIT
8	digestive/alimentary	MP:0005381	10.31	ABL1 BRAF CCND1 CDKN2A EGFR HRAS
9	cellular	MP:0005384	10.27	ABL1 BRAF CCND1 CDK2AP1 CDKN2A EGFR
10	craniofacial	MP:0005382	10.26	ABL1 BRAF CCND1 CDK2AP1 EGFR HRAS
11	no phenotypic analysis	MP:0003012	10.25	CDKN2A CYP1A1 EGFR HRAS KIT PIK3CA
12	embryo	MP:0005380	10.25	ABL1 BRAF CDK2AP1 CDKN2A EGFR KIT
13	cardiovascular system	MP:0005385	10.25	ABL1 BRAF CCND1 CDKN2A EGFR HRAS
14	liver/biliary system	MP:0005370	10.22	ABL1 BRAF CDKN2A CYP1A1 EGFR KIT
15	immune system	MP:0005387	10.22	ABL1 BRAF CCND1 CDKN2A CYP1A1 EGFR
16	renal/urinary system	MP:0005367	10.19	BRAF EGFR HRAS KIT RARB RB1
17	respiratory system	MP:0005388	10.15	ABL1 BRAF CCND1 CDKN2A EGFR HRAS
18	reproductive system	MP:0005389	10.1	BRAF CCND1 CDKN2A EGFR KIT LRRC56
19	pigmentation	MP:0001186	10.09	BRAF CDKN2A EGFR KIT RB1 TP53
20	hearing/vestibular/ear	MP:0005377	10.09	BRAF EGFR GSTM1 KIT RARB RB1
21	skeleton	MP:0005390	10.03	ABL1 BRAF CCND1 CDKN2A EGFR HRAS
22	vision/eye	MP:0005391	9.9	ABL1 BRAF CCND1 CDKN2A EGFR KIT
23	mortality/aging	MP:0010768	9.86	ABL1 BRAF CCND1 CDK2AP1 CDKN2A CYP1A1
24	integument	MP:0010771	9.4	BRAF CCND1 CDKN2A EGFR HRAS KIT

Sources

Drugs & Therapeutics for Lip and Oral Cavity Cancer

Drugs for Lip and Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Racepinephrine

Approved, Vet_approved

Phase 4

51-43-4, 329-65-7

838 5816

Dopexamine

Approved, Investigational

Phase 4

86197-47-9

55483

Norepinephrine

Approved

Phase 4

51-41-2

439260

Dobutamine

Approved

Phase 4

34368-04-2

36811

Dopamine Agents

Phase 4

Epinephryl borate

Phase 4

Cardiotonic Agents

Phase 4

Bronchodilator Agents

Phase 4

Adrenergic beta-Agonists

Phase 4

Adrenergic alpha-Agonists

Phase 4

Anti-Asthmatic Agents

Phase 4

Adrenergic Agonists

Phase 4

Adrenergic Agents

Phase 4

Dopamine agonists

Phase 4

Vasodilator Agents

Phase 4

Vasoconstrictor Agents

Phase 4

Respiratory System Agents

Phase 4

Mydriatics

Phase 4

Sympathomimetics

Phase 4

Erlotinib

Approved, Investigational

Phase 3

183319-69-9, 183321-74-6

176870

Zinc cation

Approved, Experimental, Investigational

Phase 3

7440-66-6, 23713-49-7

32051

Zinc sulfate

Approved, Investigational

Phase 3

7733-02-0

Docetaxel

Approved, Investigational

Phase 2, Phase 3

114977-28-5

148124

Carboplatin

Approved

Phase 2, Phase 3

41575-94-4

10339178 38904

Atezolizumab

Approved, Investigational

Phase 2, Phase 3

1380723-44-3

Cetuximab

Approved

Phase 2, Phase 3

205923-56-4

Durvalumab

Approved, Investigational

Phase 2, Phase 3

1428935-60-7

Trace Elements

Phase 3

Micronutrients

Phase 3

Antimitotic Agents

Phase 2, Phase 3

Tubulin Modulators

Phase 2, Phase 3

Antineoplastic Agents, Immunological

Phase 2, Phase 3

Immunoglobulins, Intravenous

Phase 2, Phase 3

Immunoglobulins

Phase 2, Phase 3

Immunoglobulin G

Phase 2, Phase 3

Antibodies, Monoclonal

Phase 2, Phase 3

Antibodies

Phase 2, Phase 3

Plasminogen

Approved

Phase 2

9001-91-6

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Raspberry

Approved

Phase 1, Phase 2

Aminolevulinic acid

Approved

Phase 1, Phase 2

106-60-5

137

Orange

Approved

Phase 1, Phase 2

Hydroxyurea

Approved

Phase 1, Phase 2

127-07-1

3657

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Nivolumab

Approved

Phase 2

946414-94-4

Cemiplimab

Approved, Investigational

Phase 2

1801342-60-8

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Interventional clinical trials:

(show top 50) (show all 173)

#	Name	Status	NCT ID	Phase	Drugs
1	Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomised Clinical Trial	Unknown status	NCT03684707	Phase 4	Metformin Hcl 500Mg 24Hr Sa Tab
2	An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study	Completed	NCT01418118	Phase 4	Epinephrine;Norepinephrine;Dobutamine;Dopexamine
3	The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor	Recruiting	NCT03017053	Phase 4
4	Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomized Clinical Trial (Part 1)	Unknown status	NCT03685409	Phase 3	Metformin Hydrochloride 500 MG;Placebo Oral Tablet
5	Comparing the Test Characteristics of Three Oral Cancer Screening Techniques:1)Unaided Visual Examination 2)VelScope Examination and 3)Toluidine Blue Application, by Trained Primary Health Care Workers in Mumbai, India.	Unknown status	NCT00655421	Phase 3
6	Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS	Unknown status	NCT01039298	Phase 3
7	Workplace Tobacco Cessation And Oral Cancer Screening Study	Completed	NCT00750503	Phase 3
8	Erlotinib Prevention of Oral Cancer (EPOC)	Completed	NCT00402779	Phase 3	Erlotinib;Placebo
9	Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma	Completed	NCT00158652	Phase 3	5FU, Paraplatin
10	Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state)	Completed	NCT00964977	Phase 3
11	Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma	Completed	NCT00158678	Phase 3	concomitant cisplatin
12	A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma	Completed	NCT00162708	Phase 2, Phase 3	CDDP, 5 Fu
13	Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer	Completed	NCT01434394	Phase 2, Phase 3	Neo-adjuvant Erbitux-based chemotherapy
14	Efficacy of Zinc Sulfate on Concurrent Chemoradiotherapy Induced Taste Alterations in Oral Cancer Patients- A Double Blind Randomized Controlled Trial	Completed	NCT03824925	Phase 3	Placebo oral Zinc capsule;Zinc Sulfate 220 MG
15	A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers	Recruiting	NCT05063552	Phase 2, Phase 3	Carboplatin;Cisplatin;Docetaxel
16	Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer	Recruiting	NCT04333537	Phase 2, Phase 3	Imaging Agent
17	Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin	Active, not recruiting	NCT03258554	Phase 2, Phase 3
18	Virtual Preplanning of Mandibular Reconstruction (ViPMR): a Phase III Randomized Controlled Clinical Trial	Not yet recruiting	NCT05429099	Phase 2, Phase 3
19	Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401)	Terminated	NCT00537199	Phase 3	OraTest
20	Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer	Unknown status	NCT02960724	Phase 2
21	Phrase II Single Arm Study of Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral	Unknown status	NCT03008694	Phase 2
22	Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer	Unknown status	NCT02739204	Phase 2	Celecoxib
23	Evaluation of Photobiomodumation Using LED Lamp as a Curative Treatment for Oral or Oropharyngeal Mucositic Inducted by Radiation Therapy	Completed	NCT04251949	Phase 2
24	A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC)	Completed	NCT00933387	Phase 2	Cetuximab,Paclitaxel,Cisplatin
25	Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral	Completed	NCT03638622	Phase 1, Phase 2
26	Randomised Pilot Study of Therabite® Versus Wooden Spatula in the Amelioration of Trismus in Head and Neck Cancer Patients. (Trismus Trial)	Completed	NCT01733797	Phase 2
27	A Study of the Effects of PEITC on Oral Cells With Mutant p53	Completed	NCT01790204	Phase 1, Phase 2
28	Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharyngeal Cancer	Completed	NCT01440270	Phase 2	Neo-adjuvant Erbitux-based chemotherapy
29	A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer	Completed	NCT00004901	Phase 1, Phase 2	ethynyluracil;fluorouracil;hydroxyurea
30	Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention	Completed	NCT01192204	Phase 1, Phase 2	10% FBR containing bioadhesive gel;placebo gel
31	Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer	Completed	NCT01469429	Phase 1, Phase 2	chemoprevention
32	Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135]	Completed	NCT00064103	Phase 1, Phase 2
33	Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial	Completed	NCT00330382	Phase 2	Bowman-Birk inhibitor concentrate
34	Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis	Completed	NCT01806675	Phase 1, Phase 2	18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
35	Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)	Recruiting	NCT03383094	Phase 2	Pembrolizumab;Cisplatin
36	A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Recruiting	NCT04862650	Phase 2	Carboplatin;Paclitaxel
37	Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing	Recruiting	NCT02734537	Phase 2	Cisplatin
38	Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study	Recruiting	NCT05136196	Phase 2	Cabozantinib S-malate
39	Multimodality Therapy With Induction Carboplatin/Nab-Paclitaxel/Durvalumab Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck	Active, not recruiting	NCT03174275	Phase 2	Durvalumab;Carboplatin;Nab-paclitaxel;Cisplatin
40	A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma	Active, not recruiting	NCT03529422	Phase 2	Durvalumab
41	M4OC-Prevent: Metformin for Oral Cancer Prevention	Active, not recruiting	NCT02581137	Phase 2	Metformin Hydrochloride
42	A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With Cisplatin	Active, not recruiting	NCT04541355	Phase 2	Cisplatin;Sodium Thiosulfate
43	Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging	Not yet recruiting	NCT04191460	Phase 2	cRGD-ZW800-1.
44	Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line	Not yet recruiting	NCT05456022	Phase 2	Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one;Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT);Doxorubicin chemotherapeutic drug as a positive control
45	M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention	Not yet recruiting	NCT05237960	Phase 2	Extended Release Metformin Hydrochloride;Placebo Administration
46	Intraoperative Visualization of Oral Cavity Squamous Cell Carcinoma and High-Grade Dysplasia With Tozuleristide, a Fluorescent Tumor Marking Agent	Not yet recruiting	NCT05316688	Phase 1, Phase 2	Tozuleristide
47	Phase II Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Chemotherapy in Squamous Cell Carcinoma of the Oral Cavity With Molecular Endpoints	Terminated	NCT00400205	Phase 2	Docetaxel;Cisplatin;5-fluorouracil
48	Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions	Completed	NCT01604759	Phase 1
49	Phase I Study of Pre-operative Combination Therapy With Mogamulizumab (Anti-CCR4) and Nivolumab (Anti-PD-1) Against Solid Cancer Patients	Completed	NCT02946671	Phase 1
50	Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer	Completed	NCT01445405	Phase 1	Bortezomib (Velcade, PS-341);Cetuximab;Cisplatin

Search NIH Clinical Center for Lip and Oral Cavity Cancer

Sources

Genetic Tests for Lip and Oral Cavity Cancer

Sources

Anatomical Context for Lip and Oral Cavity Cancer

Organs/tissues related to Lip and Oral Cavity Cancer:

MalaCards : Tongue, Lymph Node, Endothelial, Nk Cells, Bone, Breast, Myeloid

Sources

Publications for Lip and Oral Cavity Cancer

Articles related to Lip and Oral Cavity Cancer:

(show top 50) (show all 14123)

#	Title	Authors	PMID	Year
1	Multiple single nucleotide polymorphism analysis and association of specific genotypes in FHIT, SAMD4A, and ANKRD17 in Indian patients with oral cancer. ⁶² ⁵	D'Souza W...Saranath D	28580594	2017
2	Shiga Toxin-B Targeted Gold Nanorods for Local Photothermal Treatment in Oral Cancer Clinical Samples. ⁶² ⁴¹	Navarro-Palomares E...Fanarraga ML	36466783	2022
3	Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. ⁶² ⁴⁶	Liu CJ...Lin SC	20233326	2010
4	LINC00629, a KLF10-responsive lncRNA, promotes the anticancer effects of apigenin by decreasing Mcl1 stability in oral squamous cell carcinoma. ⁴¹	Shi C...Li X	36445338	2022
5	Oral Lichen Planus and Oral Squamous Cell Carcinoma share key oncogenic signatures. ⁴¹	de Lanna CA...Cohen Goldemberg D	36450755	2022
6	Diagnostic clinical aids in oral cancer. ⁵³ ⁶²	Seoane Leston J...Diz Dios P	20371204	2010
7	Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. ⁵³ ⁶²	Fang LY...Chen YL	20040021	2010
8	Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. ⁵³ ⁶²	Lee CH...Shieh YS	20302655	2010
9	Transactivation and expression patterns of Jun and Fos/AP-1 super-family proteins in human oral cancer. ⁵³ ⁶²	Mishra A...Das BC	19653276	2010
10	[Expression of survivin, caspase-3 in oral precancerous lesions and oral squamous-cell carcinoma]. ⁵³ ⁶²	Ding YP...Sun Z	20368001	2010
11	Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extension. ⁵³ ⁶²	Chang YS...Chang JG	19879255	2010
12	KO-202125, a sauristolactam derivate, induces apoptosis to prevent KB human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression. ⁵³ ⁶²	Leem DH...Cho SD	19910795	2010
13	The association between hypoxia inducible factor-1alpha gene polymorphisms and increased susceptibility to oral cancer. ⁵³ ⁶²	Chen MK...Yang SF	19717330	2009
14	S-allylcysteine modulates the expression of E-cadherin and inhibits the malignant progression of human oral cancer. ⁵³ ⁶²	Tang FY...Hsu CY	19157822	2009
15	Modulation of EGFR by oral squamous cell carcinoma cell lines. ⁵³ ⁶²	Dang D...Ramos DM	20066875	2009
16	Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. ⁴⁶	Cervigne NK...Kamel-Reid S	19776030	2009
17	Significance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue. ⁵³ ⁶²	Sinha P...Gupta SD	19431196	2009
18	Evaluation of the cytotoxic and genotoxic effects of orthodontic bonding adhesives upon human gingival papillae through immunohistochemical expression of p53, p63 and p16. ⁵³ ⁶²	Angiero F...Tete S	19846940	2009
19	Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility. ⁵³ ⁶²	Zhuo XL...Zhang XY	20082880	2009
20	Protective role of Withaferin-A on immunoexpression of p53 and bcl-2 in 7,12-dimethylbenz(a)anthracene-induced experimental oral carcinogenesis. ⁵³ ⁶²	Panjamurthy K...Vellaichamy L	19009234	2009
21	Role of nitric oxide and antioxidant enzymes in the pathogenesis of oral cancer. ⁵³ ⁶²	Patel JB...Patel PS	20160357	2009
22	Contribution of genetic polymorphisms of stromal cell-derived factor-1 and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. ⁵³ ⁶²	Teng YH...Yang SF	19373784	2009
23	Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. ⁵³ ⁶²	Misra C...Roychoudhury S	19204927	2009
24	CCL5/CCR5 axis promotes the motility of human oral cancer cells. ⁵³ ⁶²	Chuang JY...Tang CH	19334035	2009
25	Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer. ⁵³ ⁶²	Munoz-Guerra MF...Gamallo C	19449077	2009
26	Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings. ⁵³ ⁶²	Khan Z...Bisen PS	19340865	2009
27	Overexpression of DPAGT1 leads to aberrant N-glycosylation of E-cadherin and cellular discohesion in oral cancer. ⁵³ ⁶²	Nita-Lazar M...Kukuruzinska MA	19549906	2009
28	RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo. ⁵³ ⁶²	Zhou H...Zhang C	19391133	2009
29	Expression of Fas/FasL in patients with oral lichen planus. ⁵³ ⁶²	Hadzi-Mihailovic M...Jankovic L	19810143	2009
30	Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. ⁵³ ⁶²	Chen CH...Huang CY	19525975	2009
31	Matrix metalloproteinases (MMP) 1 and MMP10 but not MMP12 are potential oral cancer markers. ⁵³ ⁶²	Yen CY...Chang HW	19489686	2009
32	MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset. ⁵³ ⁶²	Hamid S...Cheong SC	18804411	2009
33	Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway. ⁵³ ⁶²	Yanamoto S...Mizuno A	18804405	2009
34	Expression of metallothionein and p53 antigens are correlated in oral squamous cell carcinoma. ⁵³ ⁶²	Cardoso SV...De Aguiar MC	19414363	2009
35	Pin1 overexpression is associated with poor differentiation and survival in oral squamous cell carcinoma. ⁵³ ⁶²	Leung KW...Lu PJ	19288014	2009
36	Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions. ⁵³ ⁶²	Pu X...Wu X	19197984	2009
37	Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma. ⁵³ ⁶²	Goulart Filho JA...Galvao HC	19239949	2009
38	Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. ⁵³ ⁶²	Sheu JJ...Tsai FJ	19276369	2009
39	E-Cadherin truncation and sialyl Lewis-X overexpression in oral squamous cell carcinoma and oral precancerous conditions. ⁵³ ⁶²	Shah MH...Patel PS	19152244	2009
40	Expression of p16 in oral cancer and premalignant lesions. ⁵³ ⁶²	Buajeeb W...Sanguansin S	19192055	2009
41	GSTM1, GSTT1 and CYP1A1 polymorphisms and risk of oral cancer: a case-control study in Jakarta, Indonesia. ⁵³ ⁶²	Amtha R...Purwanto D	19469619	2009
42	CYP1A1 and GSTM1 polymorphisms and oral cancer risk: association studies via evidence-based meta-analyses. ⁵³ ⁶²	Zhuo W...Chen Z	19160101	2009
43	Prevalence of CYP1A1 and GST polymorphisms in the population of northeastern India and susceptibility of oral cancer. ⁵³ ⁶²	Chatterjee S...Talukder G	19718946	2009
44	Oral epithelial hyperplasia in diabetes mellitus. ⁵³ ⁶²	Girtan M...Forna N	20067171	2009
45	Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients. ⁵³ ⁶²	Kobayashi J...Sato N	19123955	2009
46	Telomere attrition and telomerase activity are associated with GSTM1 polymorphism in oral cancer. ⁵³ ⁶²	Sainger RN...Patel PS	19729828	2009
47	Effects of epidermal growth factor on the invasion activity of the oral cancer cell lines HSC3 and SAS. ⁵³ ⁶²	Ohnishi Y...Kakudo K	18485796	2008
48	RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells. ⁵³ ⁶²	Liang X...Mao Z	18486529	2008
49	Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. ⁵³ ⁶²	Chen X...Li G	18701437	2008
50	Multiple aberrations of chromosome 3p detected in oral premalignant lesions. ⁵³ ⁶²	Tsui IF...Lam WL	19138989	2008

Sources

Genes for Lip and Oral Cavity Cancer

Genes related to Lip and Oral Cavity Cancer (11 elite genes):

(show all 31)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TP53	Tumor Protein P53	Protein Coding	433.47	Pathogenic ⁵ Likely pathogenic ⁵ Novoseek inferred ⁵³	17595776 10621843 12172574 (more) 14507241 11259085 10493967 9274528 12481427 10982955 18701437 10621851 14582705 9699529 7633286 8670041 8012986 9450841 8173031 18555592 15596295 15328987 10934161 10799741 19009234 8443743 11807792 9425746 8208528 8239512 14577584 12167423 8945609 9307713 10895614 9525287 16007067 20067171 9410611 7549756 8074821 19846940 11505268 11299765 11012984 10738117 10529014 9400993 1381431 20082880 16011614 11503976 11287282 11120478 10226946 9464946 16841438 18585839 14586406 10503863 8746270 16552233 16334163 15981211 14744758 10873097 7527509 14719105 13679204 12632080 12530090 11169517 9748133 8608985 19414363 1432735 17052595 16161051 16271069 12630078 12509970 10699989 10452165 7910088 19204927 19340865 17384243 16142358 14511359 12684640 11577668 11337272 9769393 9056890 8649801 7703804 8050814 18350375 15551755 11287278
2	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	432.49	Pathogenic ⁵ Likely pathogenic ⁵ Novoseek inferred ⁵³	11012984 10694953 14693237 (more) 12684640 15492849 18247379 18268126 16449996 16799478 10745173 16161051 14586406 14500697 16552233 19431196 17052587 11120478 16791592 17893905 12234999 14719099 19192055 19846940 11577668
3	RB1	RB Transcriptional Corepressor 1	Protein Coding	404.08	Pathogenic ⁵ Novoseek inferred ⁵³	8239512 10389982
4	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	402.96	Pathogenic ⁵ Novoseek inferred ⁵³	16488657 19879255 19380522
5	ABL1	ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase	Protein Coding	400	Pathogenic ⁵
6	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	400	Pathogenic ⁵
7	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	400	Pathogenic ⁵
8	LRRC56	Leucine Rich Repeat Containing 56	Protein Coding	400	Pathogenic ⁵
9	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	400	Pathogenic ⁵
10	STK11	Serine/Threonine Kinase 11	Protein Coding	400	Pathogenic ⁵
11	MIR31	MicroRNA 31	RNA Gene	350	Causal ⁴⁶	20233326
12	MIR21	MicroRNA 21	RNA Gene	50	Unspecified ⁴⁶	19776030
13	MIR345	MicroRNA 345	RNA Gene	50	Unspecified ⁴⁶	19776030
14	EGFR	Epidermal Growth Factor Receptor	Protein Coding	31.15	Likely pathogenic ⁵ Novoseek inferred ⁵³	20302655 17653341 18261460 (more) 10212811 12822012 12162763 19276369 17305640 16007067 20066875 15314969 8180574 9588705 17404024 12912971 18061531 16552233 14633702 17936675 16799709 12183435 18347929 12220351 15791567 19653276
15	CDK2AP1	Cyclin Dependent Kinase 2 Associated Protein 1	Protein Coding	8.42	Novoseek inferred ⁵³	11555592
16	GSTM1	Glutathione S-Transferase Mu 1	Protein Coding	7.52	Novoseek inferred ⁵³	12016153 19469619 11564581 (more) 10762000 11246217 17461521 9332761 19160101 17418613 19729828 7844900 10793329 8552885 9367063 14735473 17307803 14662415 19718946
17	KRT13	Keratin 13	Protein Coding	7.13	Novoseek inferred ⁵³	14654899 11098092 9574953
18	CCND1	Cyclin D1	Protein Coding	7.01	Novoseek inferred ⁵³	16488657 12097237 16007067 (more) 10389982 11267947 19288014 10766394 16334163 16172916 18061526 15791567 17893905 20302655
19	CYP1A1	Cytochrome P450 Family 1 Subfamily A Member 1	Protein Coding	6.63	Novoseek inferred ⁵³	19469619 17461521 19160101 (more) 9332761 19718946 16488179 11564581 10793329 8552885 17307803
20	RARB	Retinoic Acid Receptor Beta	Protein Coding	6.4	Novoseek inferred ⁵³	16449996 9307265 11173543 (more) 11149416
21	GSTM3	Glutathione S-Transferase Mu 3	Protein Coding	6.27	Novoseek inferred ⁵³	12016153 10762000 14735473
22	ADH1C	Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide	Protein Coding	6.21	Novoseek inferred ⁵³	11802217
23	KRT19	Keratin 19	Protein Coding	6.16	Novoseek inferred ⁵³	9574953 12419140
24	CDH1	Cadherin 1	Protein Coding	6.08	Novoseek inferred ⁵³	19157822 17685455 16449996 (more) 19152244 20302655 12003581 18804405 14983378 15328184 12375267 12684618 19549906
25	GSTT1	Glutathione S-Transferase Theta 1	Protein Coding	6.03	Novoseek inferred ⁵³	19469619 12016153 11564581 (more) 9367063 11246217 17418613 19718946 14735473 15878757 17307803
26	SLC7A5	Solute Carrier Family 7 Member 5	Protein Coding	6.03	Novoseek inferred ⁵³	15274339 15036654 15863273
27	MMP9	Matrix Metallopeptidase 9	Protein Coding	6	Novoseek inferred ⁵³	17498910 17252594 19334035 (more) 20040021 12789153 18065684 17617834 18485796 15743691 16496371 19391133 17944751 18234959
28	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	5.93	Novoseek inferred ⁵³	15892674 18356024 12516959 (more) 15461861 15756036 12747975 18467819 19239949 18381950 12738747 17595767 16822500 11140899 17624243 12542827 17016639 18695912 19197984 10874015 15796182 19910795 18674950 12870656 14674624
29	MMP2	Matrix Metallopeptidase 2	Protein Coding	5.75	Novoseek inferred ⁵³	17167983 17252594 12789153 (more) 19525975 8985100 17944751 15743691 8422010 19391133 16496371 18061521
30	CASP3	Caspase 3	Protein Coding	5.7	Novoseek inferred ⁵³	16225760 16519769 16807885 (more) 20368001 18631371
31	IVL	Involucrin	Protein Coding	5.61	Novoseek inferred ⁵³	16011614

Sources

Variations for Lip and Oral Cavity Cancer

ClinVar genetic disease variations for Lip and Oral Cavity Cancer:

⁵ (show all 48)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	GRIK2	NM_021956.5(GRIK2):c.2086-16819C>T	SNV	Association	252988	rs1335022	GRCh37: 6:102466397-102466397 GRCh38: 6:102018522-102018522
2	PREX2	NM_024870.4(PREX2):c.142-2489C>T	SNV	Association	252989	rs4512367	GRCh37: 8:68927592-68927592 GRCh38: 8:68015357-68015357
3	MMP2	NM_004530.5(MMP2):c.-1586C>T	SNV	Association	429032	rs243865	GRCh37: 16:55511806-55511806 GRCh38: 16:55477894-55477894
4	SNTB1	NM_021021.4(SNTB1):c.571+12964G>A	SNV	Association	430630	rs10090787	GRCh37: 8:121810549-121810549 GRCh38: 8:120798309-120798309
5	SAMD4A	NM_015589.6(SAMD4A):c.1176+4220T>C	SNV	Association	430718	rs1957358	GRCh37: 14:55222475-55222475 GRCh38: 14:54755757-54755757
6	ANKRD17	NM_032217.5(ANKRD17):c.7731G>A (p.Thr2577=)	SNV	Association	430719	rs2306058	GRCh37: 4:73942678-73942678 GRCh38: 4:73076961-73076961
7	CNTN4	NM_175607.3(CNTN4):c.55+61947C>T	SNV	Association	430714	rs9849237	GRCh37: 3:2675189-2675189 GRCh38: 3:2633505-2633505
8	FHIT	NM_002012.4(FHIT):c.104-196657C>A	SNV	Association	431027	rs11130760	GRCh37: 3:60196537-60196537 GRCh38: 3:60210809-60210809
9	LNX1	NM_001126328.3(LNX1):c.381-27505G>A	SNV	Association Not Found	619293	rs1435218	GRCh37: 4:54401899-54401899 GRCh38: 4:53535732-53535732
10	CCDC3	NM_031455.4(CCDC3):c.550-478A>G	SNV	Association Not Found	619294	rs4748011	GRCh37: 10:12941157-12941157 GRCh38: 10:12899157-12899157
11	RASGRP3	NM_170672.3(RASGRP3):c.-261+9727G>T	SNV	Association	236028	rs2124437	GRCh37: 2:33682737-33682737 GRCh38: 2:33457670-33457670
12	TP53	NM_000546.6(TP53):c.215C>G (p.Pro72Arg)	SNV	Pathogenic	12351	rs1042522	GRCh37: 17:7579472-7579472 GRCh38: 17:7676154-7676154
13	TP53	NM_000546.6(TP53):c.455C>T (p.Pro152Leu)	SNV	Pathogenic	142766	rs587782705	GRCh37: 17:7578475-7578475 GRCh38: 17:7675157-7675157
14	TP53	NM_000546.6(TP53):c.472C>T (p.Arg158Cys)	SNV	Pathogenic	127812	rs587780068	GRCh37: 17:7578458-7578458 GRCh38: 17:7675140-7675140
15	TP53	NM_000546.6(TP53):c.493C>T (p.Gln165Ter)	SNV	Pathogenic	182930	rs730882001	GRCh37: 17:7578437-7578437 GRCh38: 17:7675119-7675119
16	TP53	NM_000546.6(TP53):c.517G>A (p.Val173Met)	SNV	Pathogenic	233951	rs876660754	GRCh37: 17:7578413-7578413 GRCh38: 17:7675095-7675095
17	KIT	NM_000222.3(KIT):c.1621A>C (p.Met541Leu)	SNV	Pathogenic	41599	rs3822214	GRCh37: 4:55593464-55593464 GRCh38: 4:54727298-54727298
18	STK11	NM_000455.5(STK11):c.1071G>T (p.Glu357Asp)	SNV	Pathogenic	412537	rs556651007	GRCh37: 19:1223134-1223134 GRCh38: 19:1223135-1223135
19	CDKN2A	NM_000077.5(CDKN2A):c.238C>T (p.Arg80Ter)	SNV	Pathogenic	9409	rs121913388	GRCh37: 9:21971120-21971120 GRCh38: 9:21971121-21971121
20	TP53	NM_000546.6(TP53):c.524G>A (p.Arg175His)	SNV	Pathogenic	12374	rs28934578	GRCh37: 17:7578406-7578406 GRCh38: 17:7675088-7675088
21	CDKN2A	NM_000077.5(CDKN2A):c.330G>A (p.Trp110Ter)	SNV	Pathogenic	376303	rs121913389	GRCh37: 9:21971028-21971028 GRCh38: 9:21971029-21971029
22	TP53	NM_000546.6(TP53):c.376-1G>A	SNV	Pathogenic	481003	rs868137297	GRCh37: 17:7578555-7578555 GRCh38: 17:7675237-7675237
23	TP53	NM_000546.6(TP53):c.743G>A (p.Arg248Gln)	SNV	Pathogenic	12356	rs11540652	GRCh37: 17:7577538-7577538 GRCh38: 17:7674220-7674220
24	TP53	NM_000546.6(TP53):c.638G>A (p.Arg213Gln)	SNV	Pathogenic	135359	rs587778720	GRCh37: 17:7578211-7578211 GRCh38: 17:7674893-7674893
25	TP53	NM_000546.6(TP53):c.722C>T (p.Ser241Phe)	SNV	Pathogenic	12359	rs28934573	GRCh37: 17:7577559-7577559 GRCh38: 17:7674241-7674241
26	TP53	NM_000546.6(TP53):c.742C>T (p.Arg248Trp)	SNV	Pathogenic	12347	rs121912651	GRCh37: 17:7577539-7577539 GRCh38: 17:7674221-7674221
27	TP53	NM_000546.6(TP53):c.731G>C (p.Gly244Ala)	SNV	Pathogenic	458560	rs985033810	GRCh37: 17:7577550-7577550 GRCh38: 17:7674232-7674232
28	TP53	NM_000546.6(TP53):c.799C>T (p.Arg267Trp)	SNV	Pathogenic	141764	rs55832599	GRCh37: 17:7577139-7577139 GRCh38: 17:7673821-7673821
29	TP53	NM_000546.6(TP53):c.820G>T (p.Val274Phe)	SNV	Pathogenic	376674	rs1057520005	GRCh37: 17:7577118-7577118 GRCh38: 17:7673800-7673800
30	TP53	NM_000546.6(TP53):c.821T>G (p.Val274Gly)	SNV	Pathogenic	376676	rs1057520006	GRCh37: 17:7577117-7577117 GRCh38: 17:7673799-7673799
31	ABL1	NM_005157.6(ABL1):c.764A>T (p.Glu255Val)	SNV	Pathogenic	376091	rs121913449	GRCh37: 9:133738364-133738364 GRCh38: 9:130862977-130862977
32	ABL1	NM_005157.6(ABL1):c.1187A>G (p.His396Arg)	SNV	Pathogenic	376097	rs121913454	GRCh37: 9:133750356-133750356 GRCh38: 9:130874969-130874969
33	HRAS, LRRC56	NM_005343.4(HRAS):c.182A>T (p.Gln61Leu)	SNV	Pathogenic	376033	rs121913233	GRCh37: 11:533874-533874 GRCh38: 11:533874-533874
34	PIK3CA	NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala)	SNV	Pathogenic	376473	rs1057519927	GRCh37: 3:178936083-178936083 GRCh38: 3:179218295-179218295
35	HRAS, LRRC56	NM_005343.4(HRAS):c.38G>T (p.Gly13Val)	SNV	Pathogenic	180848	rs104894226	GRCh37: 11:534285-534285 GRCh38: 11:534285-534285
36	RB1	NM_000321.3(RB1):c.2039T>C (p.Ile680Thr)	SNV	Pathogenic	977767	rs1949384455	GRCh37: 13:49033902-49033902 GRCh38: 13:48459766-48459766
37	TP53	NM_000546.6(TP53):c.610G>T (p.Glu204Ter)	SNV	Pathogenic	977783	rs2073336758	GRCh37: 17:7578239-7578239 GRCh38: 17:7674921-7674921
38	HRAS, LRRC56	NM_005343.4(HRAS):c.35G>A (p.Gly12Asp)	SNV	Pathogenic	12612	rs104894230	GRCh37: 11:534288-534288 GRCh38: 11:534288-534288
39	HRAS, LRRC56	NM_005343.4(HRAS):c.37G>C (p.Gly13Arg)	SNV	Pathogenic	35554	rs104894228	GRCh37: 11:534286-534286 GRCh38: 11:534286-534286
40	HRAS, LRRC56	NM_005343.4(HRAS):c.181C>A (p.Gln61Lys)	SNV	Pathogenic	12601	rs28933406	GRCh37: 11:533875-533875 GRCh38: 11:533875-533875
41	TP53	NM_000546.6(TP53):c.916C>T (p.Arg306Ter)	SNV	Pathogenic	142144	rs121913344	GRCh37: 17:7577022-7577022 GRCh38: 17:7673704-7673704
42	PIK3CA	NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)	SNV	Pathogenic	13652	rs121913279	GRCh37: 3:178952085-178952085 GRCh38: 3:179234297-179234297
43	PIK3CA	NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys)	SNV	Pathogenic	31944	rs121913273	GRCh37: 3:178936082-178936082 GRCh38: 3:179218294-179218294
44	HRAS, LRRC56	NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)	SNV	Pathogenic	12602	rs104894229	GRCh37: 11:534289-534289 GRCh38: 11:534289-534289
45	BRAF	NM_004333.6(BRAF):c.1277G>C (p.Arg426Thr)	SNV	Pathogenic	977765	rs1801030116	GRCh37: 7:140482858-140482858 GRCh38: 7:140783058-140783058
46	CDKN2A	NM_000077.5(CDKN2A):c.233_234del (p.Leu78fs)	MICROSAT	Likely Pathogenic	977782	rs1819713922	GRCh37: 9:21971124-21971125 GRCh38: 9:21971125-21971126
47	EGFR	NM_005228.5(EGFR):c.2235_2237del (p.Glu746del)	DEL	Likely Pathogenic	977766	rs1786518484	GRCh37: 7:55242464-55242466 GRCh38: 7:55174771-55174773
48	TP53	NM_000546.6(TP53):c.902del (p.Pro301fs)	DEL	Likely Pathogenic	233908	rs876660726	GRCh37: 17:7577036-7577036 GRCh38: 17:7673718-7673718

Copy number variations for Lip and Oral Cavity Cancer from CNVD:

⁶ (show top 50) (show all 92)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	16000	1	120982663	144003083	Loss		Oral cancer
2	18683	1	147134204	147499075	Loss		Oral cancer
3	22566	1	167493797	167507911	Loss	NME7	Oral cancer
4	25915	1	195026732	195048237	Gain		Oral cancer
5	25916	1	195026732	195104236	Gain		Oral cancer
6	30920	1	246713386	246852155	Loss		Oral cancer
7	35162	1	604268	4312064	Gain		Oral cancer
8	41154	10	138235	42150788	Loss		Oral cancer
9	42635	10	37475290	37508431	Loss		Oral cancer
10	43408	10	46396192	46516611	Loss		Oral cancer
11	48616	11	101407278	102165885	Gain		Oral cancer
12	49060	11	102611683	110151240	Loss		Oral cancer
13	50726	11	119044645	133316524	Loss		Oral cancer
14	52672	11	186966	2789993	Gain		Oral cancer
15	55431	11	52900000	134452384	Gain		Oral cancer
16	56752	11	60970713	78077527	Gain		Oral cancer
17	58595	11	68654476	70150073	Gain		Oral cancer
18	79103	13	6365	44752	Loss		Oral cancer
19	82813	14	15600000	106368585	Gain		Oral cancer
20	83220	14	19560721	22142166	Gain		Oral cancer
21	83591	14	21538460	22005864	Gain		Oral cancer
22	85535	14	48265939	80627188	Gain		Oral cancer
23	88199	14	87604117	106349785	Gain		Oral cancer
24	89600	15	18741744	19805989	Loss		Oral cancer
25	89601	15	18741744	20060090	Gain		Oral cancer
26	101423	16	36766	2592859	Gain		Oral cancer
27	106087	16	85963377	88690615	Gain		Oral cancer
28	118416	17	77385789	78462808	Gain		Oral cancer
29	120365	18	24990733	76110993	Loss		Oral cancer
30	124096	19	1	28500000	Gain		Oral cancer
31	127007	19	232109	258746	Gain		Oral cancer
32	133960	19	8275	236875	Loss		Oral cancer
33	136827	2	133504494	133812256	Loss	NCKAP5	Oral cancer
34	144179	2	242501268	242717042	Gain		Oral cancer
35	150414	20	1	27100000	Gain		Oral cancer
36	151218	20	18609	5869816	Gain		Oral cancer
37	151741	20	24728423	25680524	Gain		Oral cancer
38	152139	20	29436566	62363603	Gain		Oral cancer
39	155361	20	55096989	59483462	Gain		Oral cancer
40	155973	20	59483462	62194881	Gain		Oral cancer
41	160312	22	134684	14797037	Loss		Oral cancer
42	164561	22	37689087	37715408	Loss		Oral cancer
43	166146	3	1	91700000	Deletion		Oral cancer
44	166162	3	1	91700000	Loss		Oral cancer
45	167591	3	121355348	144551988	Gain		Oral cancer
46	169747	3	145187343	199379595	Gain		Oral cancer
47	171086	3	163941201	164138371	Loss		Oral cancer
48	172647	3	185019156	185896384	Gain		Oral cancer
49	175342	3	39095	9150490	Loss	CHL1	Oral cancer
50	175343	3	39095	9150490	Loss	GRM7	Oral cancer

Sources

Expression for Lip and Oral Cavity Cancer

Search GEO for disease gene expression data for Lip and Oral Cavity Cancer.

Sources

Pathways for Lip and Oral Cavity Cancer

Pathways related to Lip and Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 84)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.83	TP53 RB1 PIK3CA KIT HRAS EGFR
2	Signal Transduction ⁶⁶	13.8	TP53 STK11 RARB PIK3CA KIT HRAS
3	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.8	ABL1 BRAF CCND1 CDKN2A EGFR HRAS
4	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.73	TP53 RB1 KIT HRAS EGFR CDKN2A
5	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.49	ABL1 BRAF CCND1 CDKN2A EGFR HRAS
6	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.97	CCND1 EGFR HRAS KIT PIK3CA STK11
7	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.88	BRAF CCND1 HRAS PIK3CA TP53
8	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.87	PIK3CA KIT HRAS EGFR BRAF
9	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.87	PIK3CA KIT HRAS EGFR BRAF
10	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.7	TP53 RB1 HRAS EGFR BRAF
11	Malignant pleural mesothelioma ⁷⁴	12.67	TP53 PIK3CA KIT HRAS EGFR CDKN2A
12	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.56	TP53 RB1 RARB PIK3CA KIT HRAS
13	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects ⁶⁶ Show member pathways Aberrant regulation of mitotic cell cycle due to RB1 defects ⁶⁶ Aberrant regulation of mitotic exit in cancer due to RB1 defects ⁶⁶ Cell cycle Cell cycle (generic schema) ²² Cell cycle Regulation of G1/S transition (part 2) ²² Cyclin D associated events in G1 ⁶⁶ Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) ⁶⁶ Defective translocation of RB1 mutants to the nucleus ⁶⁶ Diseases of mitotic cell cycle ⁶⁶ Drug-mediated inhibition of CDK4/CDK6 activity ⁶⁶ G1 Phase ⁶⁶ G2 Phase ⁶⁶ Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes ⁶⁶ PTK6 Regulates Cell Cycle ⁶⁶	12.53	RB1 CDKN2A CCND1 ABL1
14	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.53	TP53 PIK3CA HRAS EGFR BRAF
15	Mitotic G1 phase and G1/S transition ⁶⁶ Show member pathways G1/S Transition ⁶⁶	12.51	RB1 CDKN2A CCND1 ABL1
16	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.5	BRAF CCND1 HRAS PIK3CA TP53
17	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.47	TP53 PIK3CA HRAS EGFR
18	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.47	BRAF CCND1 CDKN2A EGFR HRAS KIT
19	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.45	PIK3CA HRAS EGFR CCND1
20	MAPK signaling pathway ⁷⁴	12.44	BRAF EGFR HRAS TP53
21	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.43	PIK3CA KIT HRAS EGFR BRAF
22	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.36	PIK3CA HRAS EGFR CCND1
23	Focal adhesion ⁷⁴	12.32	PIK3CA HRAS EGFR CCND1 BRAF
24	PDGFR-beta signaling pathway ⁶¹ Show member pathways ErbB1 downstream signaling ⁶¹	12.31	PIK3CA EGFR BRAF ABL1
25	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.3	TP53 PIK3CA HRAS CCND1
26	Vitamin D receptor pathway ⁷⁴	12.29	KRT13 CYP1A1 CDKN2A CCND1
27	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.29	TP53 RB1 PIK3CA KIT HRAS EGFR
28	Development Endothelin-1/EDNRA transactivation of EGFR ²² Show member pathways Cytoskeleton remodeling FAK signaling ²² Development Endothelin-1/EDNRA signaling ²²	12.27	PIK3CA HRAS EGFR CCND1
29	Cell cycle ⁷⁴ Show member pathways G1 to S cell cycle control ⁷⁴	12.27	TP53 RB1 CDKN2A CCND1 ABL1
30	Ras signaling ⁷⁴	12.27	PIK3CA KIT HRAS EGFR ABL1
31	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.25	TP53 RB1 CCND1 ABL1
32	Colorectal Cancer Metastasis ⁶⁴	12.23	TP53 EGFR CCND1 BRAF
33	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.17	PIK3CA HRAS EGFR CCND1
34	AMP-activated protein kinase signaling ⁷⁴ Show member pathways AMPK Signaling Pathway ⁶⁷ Leptin and adiponectin ⁷⁴	12.16	HRAS PIK3CA STK11 TP53
35	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	12.15	TP53 RB1 CCND1 ABL1
36	Cyclins and Cell Cycle Regulation ⁶⁴ Show member pathways Cell Cycle Control by BTG Proteins ⁶⁴ G1-S Phase Transition ⁶⁴	12.15	TP53 RB1 CDKN2A CCND1
37	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.15	TP53 PIK3CA HRAS CDKN2A CCND1
38	mTOR Signaling ⁶⁵	12.13	BRAF EGFR STK11 TP53
39	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.13	BRAF CCND1 EGFR HRAS PIK3CA RB1
40	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	12.06	TP53 PIK3CA EGFR BRAF
41	Integrated breast cancer pathway ⁷⁴	12.04	TP53 STK11 RB1 EGFR CCND1 BRAF
42	Spinal cord injury ⁷⁴	12.03	TP53 RB1 EGFR CCND1
43	Senescence and autophagy in cancer ⁷⁴	11.96	TP53 RB1 HRAS CDKN2A BRAF
44	DNA damage response (only ATM dependent) ⁷⁴	11.93	TP53 PIK3CA HRAS CCND1 ABL1
45	Hippo-Merlin signaling dysregulation ⁷⁴ Show member pathways Hippo signaling regulation pathways ⁷⁴	11.89	KIT EGFR CCND1
46	Gastrin signaling pathway ⁷⁴	11.89	PIK3CA KIT HRAS EGFR CDKN2A CCND1
47	Retinoblastoma gene in cancer ⁷⁴	11.87	TP53 RB1 CCND1 ABL1
48	Small cell lung cancer ⁷⁴	11.87	CCND1 PIK3CA RARB RB1 TP53
49	Thyroid hormones production and peripheral downstream signaling effects ⁷⁴	11.85	HRAS PIK3CA TP53
50	C-MYB transcription factor network ⁶¹	11.84	KIT GSTM1 CDKN2A CCND1

Sources

GO Terms for Lip and Oral Cavity Cancer

Biological processes related to Lip and Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 26)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell population proliferation	GO:0008285	10.27	TP53 STK11 RB1 MIR21 HRAS CDKN2A
2	positive regulation of gene expression	GO:0010628	10.23	TP53 MIR21 KIT HRAS CDKN2A BRAF
3	negative regulation of gene expression	GO:0010629	10.21	TP53 RB1 PIK3CA MIR21 HRAS
4	negative regulation of neuron apoptotic process	GO:0043524	10.21	BRAF CCND1 HRAS PIK3CA
5	positive regulation of ERK1 and ERK2 cascade	GO:0070374	10.21	ABL1 BRAF EGFR HRAS MIR21
6	cell cycle	GO:0007049	10.2	TP53 STK11 RB1 CDKN2A CDK2AP1 CCND1
7	negative regulation of cell growth	GO:0030308	10.19	CDKN2A RB1 STK11 TP53
8	Ras protein signal transduction	GO:0007265	10.1	TP53 RB1 HRAS CDKN2A
9	positive regulation of G1/S transition of mitotic cell cycle	GO:1900087	10.07	EGFR CYP1A1 CCND1
10	T cell receptor signaling pathway	GO:0050852	10.07	ABL1 BRAF HRAS PIK3CA STK11
11	cellular senescence	GO:0090398	10.06	ABL1 CDKN2A HRAS TP53
12	phosphorylation	GO:0016310	10.03	STK11 PIK3CA KIT EGFR CDKN2A BRAF
13	digestive tract development	GO:0048565	10.01	RB1 KIT CYP1A1
14	epidermal growth factor receptor signaling pathway	GO:0007173	10.01	PIK3CA EGFR BRAF ABL1
15	regulation of cell population proliferation	GO:0042127	9.97	TP53 KIT HRAS EGFR BRAF ABL1
16	regulation of cell cycle	GO:0051726	9.97	ABL1 CCND1 CDKN2A HRAS RB1 STK11
17	cellular response to gamma radiation	GO:0071480	9.95	TP53 MIR21 HRAS
18	myeloid progenitor cell differentiation	GO:0002318	9.92	KIT BRAF
19	positive regulation of extracellular matrix organization	GO:1903055	9.87	RB1 ABL1
20	response to UV-A	GO:0070141	9.83	CCND1 EGFR
21	positive regulation of protein phosphorylation	GO:0001934	9.73	MIR21 HRAS EGFR CDK2AP1 CCND1 BRAF
22	positive regulation of vascular associated smooth muscle cell differentiation	GO:1905065	9.69	KIT MIR21
23	programmed cell death	GO:0012501	9.65	TP53 RARB KIT
24	negative regulation of mitotic cell cycle	GO:0045930	9.65	TP53 RB1 MIR21 ABL1
25	positive regulation of miRNA maturation	GO:1903800	9.62	TP53 EGFR
26	cell population proliferation	GO:0008283	9.23	TP53 RB1 RARB KIT EGFR CYP1A1

Molecular functions related to Lip and Oral Cavity Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	enzyme binding	GO:0019899	9.9	CCND1 CYP1A1 EGFR GSTM1 RB1 TP53
2	protein tyrosine kinase activity	GO:0004713	9.87	KIT EGFR BRAF ABL1
3	disordered domain specific binding	GO:0097718	9.65	TP53 RB1 CDKN2A
4	protein kinase activity	GO:0004672	9.61	STK11 KIT EGFR CCND1 BRAF ABL1
5	kinase activity	GO:0016301	9.32	STK11 PIK3CA KIT EGFR CDKN2A CCND1